Tepotinib in Cholangiocarcinoma with MET Amplification: A Case Report

Yen-Hao Chen,Yu-Ting Huang,Fang-Ying Kuo

DOI: https://doi.org/10.2147/ott.s483155

IF: 4

2024-10-30

OncoTargets and Therapy

Abstract:Yen-Hao Chen, 1– 4, &ast Yu-Ting Huang, 3, &ast Fang-Ying Kuo 5 1 Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan; 2 School of Medicine, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan; 3 School of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan; 4 Department of Nursing, School of Nursing, Fooyin University, Kaohsiung, 831, Taiwan; 5 Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan &astThese authors contributed equally to this work Correspondence: Yen-Hao Chen, Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, No. 123, Dapi Road, Niaosong Dist., Kaohsiung City, Kaohsiung, 833, Taiwan, Tel +886-7-7317123 ext. 8303, Fax +886-7-7322402, Email Cholangiocarcinoma is a malignant tumor that affects the bile ducts and is usually aggressive with poor prognosis. The treatment of cholangiocarcinoma depends on the stage and location of the tumor as well as the patient's overall health status. Systemic therapy, such as chemotherapy using gemcitabine and cisplatin, is the first choice for patients with cholangiocarcinoma who were inoperable. After no response to first-line chemotherapy, second-line chemotherapy or targeted therapy focusing on signaling pathway inhibition are subsequent treatment. The present report described a case of cholangiocarcinoma involving bilateral lobes of liver. He received one cycle of chemotherapy with gemcitabine plus cisplatin and exhibited rapid progression. Next-generation sequencing was performed, and the results showed that MET amplification had a gene copy number of 68. After that, he underwent tepotinib and tumor shrinkage occurred. After a follow‐up period of 12 months, the treatment response was partial response, and the benefit of tepotinib is ongoing. The development of precision medicine has expanded the paradigm of targeted therapies to increasingly favorable options in the second line and beyond, and prolong overall survival. Detecting druggable mutations (mutations potentially amenable to treatment with) for identifying a landscape of therapeutic options is imperative for managing cholangiocarcinoma. Keywords: cholangiocarcinoma, tepotinib, MET amplification, NGS Cholangiocarcinoma is a malignant tumor that affects the bile ducts. It can occur anywhere along the bile duct, from the liver to the small intestine. Based on location, cholangiocarcinoma is classified into intrahepatic, extrahepatic, and gallbladder cancers. Cholangiocarcinoma is rare; its incidence varies widely worldwide and is more common in Asia than in Western countries. The incidence of cholangiocarcinoma is also higher in individuals with certain medical conditions such as primary sclerosing cholangitis, a chronic liver disease that causes inflammation and scarring of the bile ducts, choledochal cysts, exposure to certain chemicals such as thorium dioxide or dioxin, and a history of biliary tract surgery or liver transplantation. The treatment of cholangiocarcinoma depends on the stage and location of the tumor as well as the patient's overall health. Surgery is the preferred treatment for early-stage cholangiocarcinoma. However, cholangiocarcinoma is often diagnosed at a late stage when the tumor has already spread to other parts of the body involving extensively the extraductular tissues, or local and distant draining nodes, or distant metastases, and the prognosis is poor. Therefore, systemic therapy plays an important role in the management of advanced and metastatic cholangiocarcinoma. Gemcitabine and cisplatin are the most commonly used chemotherapeutic agents for advanced cholangiocarcinoma. In the ABC-02 trial, the combination of gemcitabine and cisplatin improved the overall survival (OS) compared to gemcitabine alone in patients with advanced cholangiocarcinoma. 1 Recently, durvalumab plus gemcitabine and cisplatin has been approved as first-line systemic therapy based on its superior objective response rate, progression-free survival (PFS), and OS compared to gemcitabine and cisplatin in the TOPAZ-1 trial. 2 After no response to first-line chemotherapy, signaling pathway inhibition has emerged as a promising therapeutic option for treating cholangiocarcinoma. The ClarIDHy trial showed that ivosidenib increased OS in patients with chemotherapy-refractory cholangiocarcinoma with an IDH1 mutation. 3 In contrast, fibroblast growth factor receptor ( FGFR )2 fusions or rearrangements are pres -Abstract Truncated-

oncology,biotechnology & applied microbiology